Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2025Seminars in Ophthalmology

Recent Advances in Targeted Immunomodulatory Therapies for Chronic Ocular Surface Diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

RGRiccardo GenoveseSSSara SpeltaALAndrea Leonardi

Discussion

Loading...

Member takes

Overview

Review compares the safety, efficacy of immunosuppressive agents in chronic ocular surface diseases, highlighting JAK inhibitors' potential.

Key Points

  • Corticosteroids control acute ocular inflammation but pose risks like elevated eye pressure and cataracts.
  • Targeted immunomodulators, including JAK inhibitors and IL-1 receptor antagonists, show promising efficacy for chronic conditions.
  • Study analyzed literature from 1960 to 2024, focusing on topical therapies for ocular surface diseases.
  • The shift towards precision immunotherapy suggests a safer long-term treatment strategy for chronic inflammation.

Cite This Study

Genovese et al. (2025) studied this question.

synapsesocial.com/papers/689a0933e6551bb0af8ce519https://doi.org/10.1080/08820538.2025.2536766
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis2010 · 180 citations
  2. 2The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases1995 · 2,458 citations
  3. 3Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial2012 · 33 citations